Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 364793-93-1 | MDL No. : | MFCD11846170 |
Formula : | C10H13BrN2O | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | QAWNEXYXZJNVGB-UHFFFAOYSA-N |
M.W : | 257.13 | Pubchem ID : | 23437896 |
Synonyms : |
|
Num. heavy atoms : | 14 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.5 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 61.91 |
TPSA : | 25.36 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -7.12 cm/s |
Log Po/w (iLOGP) : | 2.48 |
Log Po/w (XLOGP3) : | 1.06 |
Log Po/w (WLOGP) : | 1.14 |
Log Po/w (MLOGP) : | 0.99 |
Log Po/w (SILICOS-IT) : | 2.43 |
Consensus Log Po/w : | 1.62 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.29 |
Solubility : | 1.33 mg/ml ; 0.00516 mol/l |
Class : | Soluble |
Log S (Ali) : | -1.18 |
Solubility : | 16.8 mg/ml ; 0.0655 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -3.47 |
Solubility : | 0.0869 mg/ml ; 0.000338 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 1.98 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P301+P312-P302+P352-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H320-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
85% | Stage #1: With sodium tris(acetoxy)borohydride; acetic acid In 1,2-dichloro-ethane at 20℃; for 0.666667 h; Stage #2: With sodium hydrogencarbonate In 1,2-dichloro-ethane |
To a RB flask containing formylpyridine (9.347 g, 1 equiv.) in 175 mL 1,2-dichloroethane (3.5 mL/mmol) was added morpholine (4.7 mL, 1.07 equiv.) followed by NaBH(OAc)3 (14.819 g, 1.4 equiv.) and acetic acid (3.1 mL, 1.07 equiv.). The flask was loosely capped and the mixture was stirred at r.t. Mixture gets slightly warm. After 40 min, the reaction was quenched with saturated NaHCO3. When the gas evolution was greatly reduced, 1M NaOH was added to bring the pH to 8-9. The two layers were separated and the aqueous layer was extracted with DCM (.x.3). The organic layer was dried over Na2SO4, filtered and solvent was removed in vacuo. The product was filtered through silica with 1000 mL 100:1 EtOAc:NH4OH to remove baseline material. The material was dissolved in 15 mL EtOAc and 150 mL hexanes was added. The mixture was allowed to sit overnight at 4° C. to crystallize. The supernatant was decanted off and the crystals were washed with a little hexanes which was decanted off. The crystals were transferred to another flask using DCM. LC-MS showed only product. The solvent from the supernatant was removed in vacuo. The remaining mixture was purified by flash column (6.5.x.8.5 cm silica) using 500 mL 8:2 EtOAc; 1400 mL 100:1 EtOAc:NH4OH. All product fractions were combined giving 10.931 g (85percent) of the 4-((6-bromopyridin-3-yl)methyl)morpholine as a yellow solid.In a RB flask, a mixture of 4-((6-bromopyridin-3-yl)methyl)morpholine (10.959 g, 1 equiv.), 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (10.478 g, 1.05 equiv.), 2M potassium phosphate solution (42.5 mL, 2 equiv.) and Pd(PPh3)4 (2.479, 0.050 equiv.)) in 210 mL dioxane (5 mL/mmol) was sparged with argon for 5 min. The flask was fitted with a septum and argon balloon and the mixture was stirred at 100° C. (amber solution). After 27 h, the mixture was allowed to cool then volume was reduced by at least half in vacuo. The remainder was diluted with water and extracted with EtOAc (.x.3). The organic layers were washed with brine, dried over Na2SO4, filtered and solvent was removed in vacuo. The material was purified by column chromatography on silica eluting with DCM:MeOH to give 10.268 g (85percent) of 4-methyl-3-(5-(morpholinomethyl)pyridin-2-yl)aniline as a very viscous dark amber oil. |
72% | With sodium tris(acetoxy)borohydride; acetic acid In 1,2-dichloro-ethane at 0 - 20℃; for 5 h; | 4-[(6-bromopyridin-3-yl)methyl]morpholine In a 50-mL round bottom flask, 6-bromopyridine-3-carbaldehyde (1.200 g, 6.45 mmol, 1.00 equiv) and morpholine (843 mg, 9.68 mmol, 1.50 equiv) were dissolved in 1,2-dichloroethane (15 mL), to which were added NaBH(OAc)3 (4.102 g, 19.35 mmol, 3.00 equiv) and acetic acid (416 mg, 10.35 mmol 1.07 equiv) at 0° C. The resulting solution was warmed up to room temperature and stirred for 5 h at room temperature. When the reaction was done, it was quenched by the addition of 20 mL sat. sodium bicarbonate solution and the pH value of the resulting mixture was adjusted to 9 using sodium hydroxide solution (1 M). The mixture was then extracted with ethyl acetate (3*30 mL) and the organic layers were combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified in a silica gel column eluting with ethyl acetate in petroleum ether (5percent to 50percent gradient) to afford 4-[(6-bromopyridin-3-yl)methyl]morpholine (1.2 g, 72percent) as light yellow solid. |
57.9% | With sodium tris(acetoxy)borohydride In 1,2-dichloro-ethane at 20℃; for 2 h; | To a solution of 6-bromonicotinaldehyde (1.0 g, 5.4 mmol) and morpholine (0.50 g, 5.7 mmol) in 1,2-dichloroethane (30 mL) was added sodium triacetoxyborohydride (1.8 g, 8.5 mmol) and the resulting mixture was stirred at room temperature for 2 h. The mixture was concentrated and purified via ISCO (eluted with MeOH in H20 0-100percent) to afford the title compound as a yellow solid (0.80 g, 57.9percent yield). MS (m/z): 256.9/258.9 (M+H)+. |
57.9% | With sodium tris(acetoxy)borohydride In 1,2-dichloro-ethane at 20℃; for 2 h; | To a solution of 6-bromonicotinaldehyde (1.0 g, 5.4 mmol) and morpholine (0.50 g, 5.7 mmol) in 1 ,2-dichloroethane (30 mL) was added sodium triacetoxyborohydride (1.8 g, 8.5 mmol) and the resulting mixture was stirred at room temperature for 2 h. The mixture was concentrated and purified via ISCO (eluted with MeOH in H20 0-100percent) to afford the title compound as a yellow solid (0.80 g, 57.9percent yield). MS (m/z): 256.9/258.9 (M+H)+. |
43% | With sodium cyanoborohydride; acetic acid In ethanol at 20℃; for 3 h; | (181a) 4-[(6-Bromopyridin-3-yl)methyl]morpholine 2-Bromo-5-formylpyridine (0.86 g, 4.6 mmol) was dissolved in ethanol (20 mL), and morpholine (0.48 mL, 5.5 mmol), acetic acid (0.37 mL, 6.4 mmol), and sodium cyanoborohydride (0.43 g, 6.9 mmol) were added thereto. The resulting mixture was stirred at room temperature for 3 hr. The solvent was evaporated under reduced pressure. To the residue, a saturated sodium carbonate aqueous solution was added. After extraction with methylene chloride, the organic layer was dried with anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (Yamazen, eluding solvent: ethyl acetate) to obtain 0.51 g (yield: 43percent) of the title compound as a white solid. 1H-NMR (400 MHz, CDCl3) δ ppm: 8.28 (1H, d, J = 2.3 Hz), 7.54 (1H, dd, J = 2.3, 8.0 Hz), 7.43 (1H, d, J = 8.0 Hz), 3.69 (4H, t, J = 4.7 Hz), 3.45 (2H, s), 2.43 (4H, t, J = 4.7 Hz). |
[ 2061979-42-6 ]
Bis((6-bromopyridin-3-yl)methyl)amine
Similarity: 0.80
[ 1231930-25-8 ]
1-((6-Bromopyridin-3-yl)methyl)-4-ethylpiperazine
Similarity: 0.79
[ 120740-10-5 ]
(6-Bromopyridin-3-yl)methanamine
Similarity: 0.73
[ 952582-08-0 ]
4-(6-Bromopyridin-3-yl)morpholine
Similarity: 0.70
[ 1802489-58-2 ]
(6-Bromo-2-methoxypyridin-3-yl)methanamine
Similarity: 0.69
[ 952582-08-0 ]
4-(6-Bromopyridin-3-yl)morpholine
Similarity: 0.70
[ 1049023-41-7 ]
4-(2-Bromopyridin-4-yl)morpholine
Similarity: 0.59
[ 64614-49-9 ]
(6-Chloropyridin-3-yl)(morpholino)methanone
Similarity: 0.58
[ 2061979-42-6 ]
Bis((6-bromopyridin-3-yl)methyl)amine
Similarity: 0.80
[ 1231930-25-8 ]
1-((6-Bromopyridin-3-yl)methyl)-4-ethylpiperazine
Similarity: 0.79
[ 120740-10-5 ]
(6-Bromopyridin-3-yl)methanamine
Similarity: 0.73
[ 952582-08-0 ]
4-(6-Bromopyridin-3-yl)morpholine
Similarity: 0.70
[ 1802489-58-2 ]
(6-Bromo-2-methoxypyridin-3-yl)methanamine
Similarity: 0.69